Genematrix Inc

Genematrix Inc has a liquidity position that is relatively strong, with a current ratio of 4.32, indicating that the company has sufficient current assets to cover its current liabilities. However, the company's free cash flow is negative at -1352489750 KRW, which suggests that it is not generating enough cash from operations to cover its capital expenditures and other cash outflows. The company's cash and equivalents amount to 2236077530 KRW, but this is offset by long-term debt of 3727881000 KRW, resulting in a net cash position that is negative after subtracting total debt. In terms of profitability, Genematrix Inc is currently unprofitable, with a net income of -1834404220 KRW and an operating income of -679131170 KRW. The company's return on equity is -0.105 and return on assets is -0.0673, both of which are negative, indicating that the company is not generating returns for its shareholders or effectively utilizing its assets. These metrics are below the industry medians for profitability and returns, suggesting that the company is underperforming relative to its peers. Genematrix Inc's revenue is primarily derived from the sale of medical diagnostic reagents, with a focus on molecular and biochemical diagnostic products. The company's geographic exposure is concentrated in Korea, as it is a Korea-based company. There is no disclosed information on revenue concentration by segment or region, but the company's operations are primarily centered around its core diagnostic product lines. The company's growth trajectory is uncertain, as it is currently reporting negative operating and net income. There is no disclosed information on revenue growth or future projections, but the company's negative free cash flow and operating cash flow suggest that it may be investing heavily in its operations or facing operational challenges. The company's capital expenditures are relatively low at -64541530 KRW, which may indicate a conservative approach to capital investment. The risk assessment for Genematrix Inc indicates a medium level of liquidity risk and a low level of dilution risk. The company's key financial flags include a negative net cash position after subtracting total debt, which could impact its ability to fund operations or invest in growth opportunities. The company's dilution potential is low, as there is no indication of significant share issuance or dilution sources in the near term. The company's debt-to-equity ratio is 0.21, which is relatively low, suggesting that it is not heavily leveraged. There are no recent events or filings disclosed in the provided data that would significantly impact the company's operations or financial position. The company's financial snapshot and valuation metrics do not indicate any major changes in its business or financial strategy in the near term.